CoreLab Partners Now Offers Semi-Automated ECG Solutions
“We are pleased to announce the release of our new semi-automated CalECG v3 solution for the analysis of ECGs” said CoreLab Partners’ President and Chief Executive Officer, Dr. Mike Woehler. “This new application represents our commitment to advancing technologies in the cardiac safety market sector and complements our established processes in our proprietary WebHeart® technology platform,” added Woehler.
The AMPS CalECG application, originally designed for the on-screen measurement of ECG signals in the context of pharmaceutical trials, is capable of handling digital
CoreLab Partners has also licensed the full set of AMPS Heart Rate Variability tools (WinHRV), which has been extensively used in the academic domain for the assessment of autonomic nervous systems changes associated with both clinical and drug-induced conditions.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025